Repare Therapeutics Inc
NASDAQ:RPTX

  • LAST PRICE
    2.9000
  • TODAY'S CHANGE (%)
    0.0900 (3.2028%)
  • Bid / Lots
    2.8800/ 9
  • Ask / Lots
    2.9100/ 2
  • Open / Previous Close
    2.8700 / 2.8100
  • Day Range
    2.8500
    2.9900
  • 52 Week Range
    2.7100
    8.4900
  • Volume
    124,260

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
RPTX
Repare Therapeutics Inc
119.5M
-1.5x
---
IPHA
Innate Pharma SA
129.9M
-3.4x
---
CSBR
Champions Oncology Inc
61.9M
-17.0x
---
DTIL
Precision BioSciences Inc
55.7M
9.6x
---
MGX
Metagenomi Inc
70.8M
-0.8x
---
CDTX
Cidara Therapeutics Inc
143.8M
-0.7x
---
As of 2024-11-25

Company Information

Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.

Contact Information

Headquarters
7210 Frederick-Banting, Suite 100ST-LAURENT, QC, Canada H4S 2A1
Phone
---
Fax
---

Executives

Independent Chairman of the Board
Thomas Civik
President, Chief Executive Officer, Director
Lloyd Segal
Chief Financial Officer, Executive Vice President
Steve Forte
Executive Vice President, Chief Scientific Officer
Michael Zinda
Executive Vice President, Chief Medical Officer
Maria Koehler

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$119.5M
Revenue (TTM)
$66.5M
Shares Outstanding
42.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.67
EPS
$-2.00
Book Value
$5.03
P/E Ratio
-1.5x
Price/Sales (TTM)
1.8
Price/Cash Flow (TTM)
---
Operating Margin
-140.91%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.